This trial found that Exparel provides superior postoperative pain control compared to bupivacaine alone in minimally invasive ventral and inguinal hernia repair patients.
- Inguinal Hernia
- Ventral Hernia
1 Primary · 2 Secondary · Reporting Duration: After 1 week post-operation
Awards & Highlights
2 Treatment Groups
Liposomal Bupivacaine (Exparel)
1 of 2
1 of 2
200 Total Participants · 2 Treatment Groups
Primary Treatment: Liposomal Bupivacaine (Exparel) · No Placebo Group · Phase < 1
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Frequently Asked Questions
How many participants are being invited to participate in this scientific investigation?
"Affirmative, the data hosted on clinicaltrials.gov suggests that this trial is currently recruiting patients for participation. This medical experiment was initially posted on March 1st 2022 and has been modified as recently as April 19th 2022. Approximately 200 individuals from a single location are needed to take part in the study." - Anonymous Online Contributor
What other research initiatives have been implemented to evaluate Liposomal Bupivacaine (Exparel)?
"Currently, the clinical trial landscape for Liposomal Bupivacaine (Exparel) includes 110 active studies with 18 trials in Phase 3. Philadelphia, Pennsylvania hosts many of these experiments but there are also 147 other locations where such research is taking place." - Anonymous Online Contributor
Are participants sought for this ongoing trial?
"Indeed, the information available on clinicaltrials.gov signifies that this medical experiment is soliciting enrolment. It was first published in March 1st 2022 and underwent its last revision on April 19th of the same year. This study seeks to enroll up to 200 patients from a single site." - Anonymous Online Contributor
In what clinical scenarios is Liposomal Bupivacaine (Exparel) regularly prescribed?
"Liposomal Bupivacaine (Exparel) is frequently prescribed for permphigus patients. It can also provide relief to individuals dealing with acute nonspecific tenosynovitis, general anesthesia, and lupus erythematosus cell related issues." - Anonymous Online Contributor